78.495 USD
-0.7 (-0.89%)
78.495 USD
0 (0%)
Overall PTCT gets a fundamental rating of 5 out of 10. We evaluated PTCT against 534 industry peers in the Biotechnology industry. PTCT has only an average score on both its financial health and profitability. PTCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make PTCT suitable for growth investing!
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
PTCT had a positive operating cash flow in the past year.
In the past 5 years PTCT always reported negative net income.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTCT has a Return On Assets of 28.43%. This is amongst the best in the industry. PTCT outperforms 97.94% of its industry peers.
PTCT has a Return On Invested Capital of 41.48%. This is amongst the best in the industry. PTCT outperforms 99.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROIC | 41.48% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTCT has a Profit Margin of 42.25%. This is amongst the best in the industry. PTCT outperforms 97.94% of its industry peers.
Looking at the Operating Margin, with a value of 52.45%, PTCT belongs to the top of the industry, outperforming 99.81% of the companies in the same industry.
PTCT has a Gross Margin of 96.83%. This is amongst the best in the industry. PTCT outperforms 96.44% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PTCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTCT has more shares outstanding
The debt/assets ratio for PTCT is higher compared to a year ago.
2.2 Solvency
PTCT has an Altman-Z score of 2.21. This is not the best score and indicates that PTCT is in the grey zone with still only limited risk for bankruptcy at the moment.
PTCT's Altman-Z score of 2.21 is fine compared to the rest of the industry. PTCT outperforms 67.79% of its industry peers.
PTCT has a debt to FCF ratio of 3.38. This is a good value and a sign of high solvency as PTCT would need 3.38 years to pay back of all of its debts.
PTCT's Debt to FCF ratio of 3.38 is amongst the best of the industry. PTCT outperforms 92.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Altman-Z | 2.21 |
ROIC/WACC5.71
WACC7.26%
2.3 Liquidity
A Current Ratio of 2.32 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Current ratio of 2.32. This is in the lower half of the industry: PTCT underperforms 70.97% of its industry peers.
A Quick Ratio of 2.26 indicates that PTCT has no problem at all paying its short term obligations.
The Quick ratio of PTCT (2.26) is worse than 69.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.07%, which is quite impressive.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 97.54%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
3.2 Future
Based on estimates for the next years, PTCT will show a very strong growth in Earnings Per Share. The EPS will grow by 25.49% on average per year.
Based on estimates for the next years, PTCT will show a quite strong growth in Revenue. The Revenue will grow by 17.10% on average per year.
EPS Next Y225.38%
EPS Next 2Y19.18%
EPS Next 3Y23.42%
EPS Next 5Y25.49%
Revenue Next Year113.44%
Revenue Next 2Y3.3%
Revenue Next 3Y9.97%
Revenue Next 5Y17.1%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.81, the valuation of PTCT can be described as very reasonable.
Based on the Price/Earnings ratio, PTCT is valued cheaper than 97.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, PTCT is valued rather cheaply.
PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaply inside the industry as 98.50% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaply inside the industry as 98.50% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.94 | ||
| EV/EBITDA | 6.2 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 23.42% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y19.18%
EPS Next 3Y23.42%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
78.495
-0.7 (-0.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.79%
Inst Owner Change-0.57%
Ins Owners0.7%
Ins Owner Change3.39%
Market Cap6.30B
Revenue(TTM)1.78B
Net Income(TTM)751.72M
Analysts78.26
Price Target80.45 (2.49%)
Short Float %12.03%
Short Ratio6.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.83%
Min EPS beat(2)23.33%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)1164.83%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)562.98%
EPS beat(12)5
Avg EPS beat(12)357.38%
EPS beat(16)5
Avg EPS beat(16)260.9%
Revenue beat(2)2
Avg Revenue beat(2)7.12%
Min Revenue beat(2)2.58%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)147.37%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)76.88%
Revenue beat(12)7
Avg Revenue beat(12)50.21%
Revenue beat(16)10
Avg Revenue beat(16)38.94%
PT rev (1m)18.43%
PT rev (3m)18.43%
EPS NQ rev (1m)41.78%
EPS NQ rev (3m)35.37%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-1.7%
Revenue NQ rev (1m)24.85%
Revenue NQ rev (3m)18.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.81 | ||
| Fwd PE | N/A | ||
| P/S | 3.54 | ||
| P/FCF | 8.94 | ||
| P/OCF | 8.81 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.2 |
EPS(TTM)7.26
EY9.25%
EPS(NY)-3.48
Fwd EYN/A
FCF(TTM)8.78
FCFY11.19%
OCF(TTM)8.91
OCFY11.35%
SpS22.16
BVpS-1.94
TBVpS-7.9
PEG (NY)0.05
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROCE | 52.5% | ||
| ROIC | 41.48% | ||
| ROICexc | 822.48% | ||
| ROICexgc | N/A | ||
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% | ||
| FCFM | 39.64% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score7
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Debt/EBITDA | 1.9 | ||
| Cap/Depr | 31.38% | ||
| Cap/Sales | 0.58% | ||
| Interest Coverage | 163.67 | ||
| Cash Conversion | 74.07% | ||
| Profit Quality | 93.81% | ||
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.21 |
F-Score7
WACC7.26%
ROIC/WACC5.71
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
EPS Next Y225.38%
EPS Next 2Y19.18%
EPS Next 3Y23.42%
EPS Next 5Y25.49%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
Revenue Next Year113.44%
Revenue Next 2Y3.3%
Revenue Next 3Y9.97%
Revenue Next 5Y17.1%
EBIT growth 1Y813.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.42%
EBIT Next 3Y50.48%
EBIT Next 5YN/A
FCF growth 1Y375.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.28%
OCF growth 3YN/A
OCF growth 5YN/A
PTC THERAPEUTICS INC / PTCT FAQ
What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PTCT.
Can you provide the valuation status for PTC THERAPEUTICS INC?
ChartMill assigns a valuation rating of 6 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.
Can you provide the profitability details for PTC THERAPEUTICS INC?
PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.
What are the PE and PB ratios of PTC THERAPEUTICS INC (PTCT) stock?
The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 10.81 and the Price/Book (PB) ratio is -40.46.